Seeing the implications
The advantage of precision medicine is that every biomarker has the potential to uncover a new opportunity.
Detecting homozygous MTAP deletions may reveal tumor vulnerability and help inform future clinical planning.1
MTAP in action
Normal cells retain MTAP, so PRMT5 uses SAM as its co-factor2
Homozygous MTAP deletion causes MTA to build up in the cell. MTA competes with SAM, partially blocking PRMT5 activity. Tumor cell survival depends on the remaining PRMT5 function, making it a target for synthetic lethality.1,2
Actions you can take now
Testing for homozygous MTAP deletion today can reveal this hidden tumor vulnerability.
Multiple clinical trials are underway to evaluate investigational approaches that aim to target this vulnerability in several solid tumors, including in NSCLC and PDAC4-6*
* |
For healthcare professional use only. The safety and efficacy of investigational agents have not been established. |
MTA=methylthioadenosine; MTAP=methylthioadenosine phosphorylase; MTR-1-P=methylthioribose-1-phosphate; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; PRMT5=protein arginine methyltransferase 5; SAM=s-adenosyl-L-methionine. |
|
References: 1. Brune MM, Prince SS, Vlajnic T, et al. MTAP as an emerging biomarker in thoracic malignancies. Lung Cancer. 2024. doi:10.1016/j.lungcan.2024.107963 2. Rodon J, Johnson ML, George B, Shah PA, Arbour KC. MTAP deletion in oncogenesis: a synthetic lethality scenario. Cancer Res. 2026;86(7):1558-1569. 3. Engstrom LD, Aranda R, Waters L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023;13(11):2412-2431. 4. Bristol Myers Squibb. A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) - CA240-0009. Updated June 9, 2026. Accessed August 4, 2026. https://www.bmsstudyconnect.com/es/en/clinical-trials/NCT06855771.html 5. Bristol Myers Squibb. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion - CA240-0029. Updated July 17, 2026. Accessed August 4, 2026. https://www.bmsstudyconnect.com/pl/en/clinical-trials/NCT07063745.html 6. Bristol Myers Squibb. A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) - CA240-0030. Updated June 2, 2026. Accessed August 4, 2026. https://www.bmsstudyconnect.com/br/en/clinical-trials/NCT07076121.html |
Explore ongoing BMS MTAP trials worldwide
